JPS6094580U
(ja)
|
1983-12-05 |
1985-06-27 |
株式会社 銭屋アルミニウム製作所 |
扉の装飾枠
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
JP2727112B2
(ja)
|
1988-04-26 |
1998-03-11 |
コニカ株式会社 |
安定なペルオキシダーゼ組成物及び安定な抗体組成物
|
US5077216A
(en)
|
1988-07-06 |
1991-12-31 |
The Trustees Of Dartmouth College |
Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen
|
JPH0341033A
(ja)
|
1989-07-07 |
1991-02-21 |
Kyowa Hakko Kogyo Co Ltd |
安定なモチリン類含有製剤
|
US5073627A
(en)
|
1989-08-22 |
1991-12-17 |
Immunex Corporation |
Fusion proteins comprising GM-CSF and IL-3
|
GB9009548D0
(en)
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Chimeric antibody and method
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5223241A
(en)
|
1990-10-01 |
1993-06-29 |
The General Hospital Corporation |
Method for early detection of allograft rejection
|
AU668349B2
(en)
|
1991-04-25 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
GB9120304D0
(en)
|
1991-09-24 |
1991-11-06 |
Erba Carlo Spa |
Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
|
JPH0597703A
(ja)
|
1991-10-04 |
1993-04-20 |
Yamanouchi Pharmaceut Co Ltd |
改変型組織プラスミノーゲン活性化因子含有組成物
|
CA2097932A1
(en)
|
1991-10-11 |
1993-04-12 |
Shojiro Yamazaki |
Antibody containing composition
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
SG55079A1
(en)
*
|
1992-12-11 |
1998-12-21 |
Dow Chemical Co |
Multivalent single chain antibodies
|
US5780021A
(en)
|
1993-03-05 |
1998-07-14 |
Georgetown University |
Method for treating type 1 diabetes using α-interferon and/or β-i
|
US5747654A
(en)
|
1993-06-14 |
1998-05-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant disulfide-stabilized polypeptide fragments having binding specificity
|
UA50708C2
(uk)
|
1993-09-03 |
2002-11-15 |
Чугай Сейяку Кабусікі Кайся |
Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
|
US6719972B1
(en)
|
1994-06-03 |
2004-04-13 |
Repligen Corporation |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
|
US6048972A
(en)
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
US8771694B2
(en)
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
ATE306930T1
(de)
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US6451523B1
(en)
|
1994-09-14 |
2002-09-17 |
Interneuron Pharmaceuticals, Inc. |
Detection of a leptin receptor variant and methods for regulating obesity
|
DE726075T1
(de)
|
1995-02-08 |
1996-12-12 |
Therapicon Srl |
Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
|
PT812136E
(pt)
|
1995-02-28 |
2001-04-30 |
Procter & Gamble |
Preparacao de bebidas nao gaseificadas com estabilidade microbiana superior
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
WO1996034892A1
(en)
|
1995-05-03 |
1996-11-07 |
Bioenhancements Ltd. |
Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
|
JPH11505704A
(ja)
|
1995-05-17 |
1999-05-25 |
リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ |
アンチcd−19抗体の単鎖可変領域フラグメントを含む免疫コンジュゲート
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US6013067A
(en)
|
1995-06-07 |
2000-01-11 |
Zymogenetics, Inc. |
Methods for increasing hematopoietic cells
|
CA2245835A1
(en)
|
1995-06-14 |
1997-01-03 |
The Regents Of The University Of California |
Novel high affinity human antibodies to tumor antigens
|
JP4435304B2
(ja)
|
1995-06-29 |
2010-03-17 |
イミュネックス・コーポレーション |
アポトーシスを誘導するサイトカイン
|
AU690474B2
(en)
|
1995-09-11 |
1998-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody againts alpha-chain of human interleukin 5 receptor
|
ATE449849T1
(de)
|
1996-01-08 |
2009-12-15 |
Genentech Inc |
Ob rezeptor-variante und liganden
|
FR2745008A1
(fr)
|
1996-02-20 |
1997-08-22 |
Ass Pour Le Dev De La Rech En |
Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
|
EP0903149A4
(en)
|
1996-03-06 |
2002-02-13 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR SCREENING SUBSTANCES INDUCING APOPTOSIS
|
DE69729283T2
(de)
|
1996-03-20 |
2005-05-25 |
Immunomedics, Inc. |
GLYKOSYLIERTE IgG ANTIKÖRPER
|
AU724689B2
(en)
|
1996-05-09 |
2000-09-28 |
Pharma Pacific Pty Ltd |
Method of treatment
|
US5908925A
(en)
|
1996-06-27 |
1999-06-01 |
Exocell, Inc. |
Genetically engineered immunoglobulins with specificity for glycated albumin
|
JP3416035B2
(ja)
|
1996-09-26 |
2003-06-16 |
中外製薬株式会社 |
ヒト副甲状腺ホルモン関連ペプチドに対する抗体
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6323000B2
(en)
|
1996-12-20 |
2001-11-27 |
Clark A. Briggs |
Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
|
US20040136951A1
(en)
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US7541034B1
(en)
|
1997-03-20 |
2009-06-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
DE69830901T2
(de)
|
1997-05-02 |
2006-05-24 |
Genentech Inc., San Francisco |
ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1999002567A2
(en)
|
1997-07-08 |
1999-01-21 |
Board Of Regents, The University Of Texas System |
Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
KR20010023866A
(ko)
|
1997-09-11 |
2001-03-26 |
나가야마 오사무 |
아포토시스를 유기하는 모노클로날 항체
|
US7531643B2
(en)
|
1997-09-11 |
2009-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody inducing apoptosis
|
CA2273223C
(en)
|
1997-09-29 |
2003-11-11 |
Raytheon Company |
Chip-size package using a polyimide pcb interposer
|
US5998593A
(en)
|
1998-03-10 |
1999-12-07 |
Abbott Laboratories |
Fluorescent enzyme substrates
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US7081360B2
(en)
|
1998-07-28 |
2006-07-25 |
Cadus Technologies, Inc. |
Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
|
US6092926A
(en)
|
1998-09-17 |
2000-07-25 |
International Business Machines Corporation |
Thermal monitoring system for semiconductor devices
|
CA2345903C
(en)
|
1998-10-16 |
2006-09-26 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Molecular pathogenicide mediated plant disease resistance
|
US20050220787A1
(en)
|
2002-11-07 |
2005-10-06 |
Lobo Peter I |
Naturally occuring IgM antibodies that bind to lymphocytes
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
EP1167388A4
(en)
|
1999-03-10 |
2002-05-29 |
Chugai Pharmaceutical Co Ltd |
APOPTOSE INDUCING SINGLE STRING FV
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
AR030019A1
(es)
|
1999-05-18 |
2003-08-13 |
Smithkline Beecham Corp |
Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
|
JP2003505344A
(ja)
|
1999-06-09 |
2003-02-12 |
ジェネンテック・インコーポレーテッド |
Apo−2LレセプターアゴニストとCPT−11の相乗効果
|
US20020028178A1
(en)
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
AU1290001A
(en)
|
1999-11-18 |
2001-05-30 |
Oxford Biomedica (Uk) Limited |
Antibodies
|
EP1238080A2
(en)
|
1999-12-14 |
2002-09-11 |
The Burnham Institute |
Bcl-g polypeptides, encoding nucleic acids and methods of use
|
AU2001256174A1
(en)
|
2000-03-01 |
2001-09-12 |
Christoph Gasche |
Mammalian interleukin-10 (il-10) receptor variants
|
TWI241345B
(en)
|
2000-03-10 |
2005-10-11 |
Chugai Pharmaceutical Co Ltd |
Apoptosis inducing polypeptide
|
ATE382055T1
(de)
|
2000-03-22 |
2008-01-15 |
Curagen Corp |
Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
|
CA2404365A1
(en)
|
2000-03-31 |
2001-10-11 |
Idec Pharmaceutical Corporation |
Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US20040058393A1
(en)
|
2000-04-17 |
2004-03-25 |
Naoshi Fukishima |
Agonist antibodies
|
AU2001246934A1
(en)
|
2000-04-17 |
2001-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Agonist antibodies
|
ATE365749T1
(de)
|
2000-05-12 |
2007-07-15 |
Gpc Biotech Ag |
Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
|
SG136804A1
(en)
|
2000-07-12 |
2007-11-29 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
ES2477996T3
(es)
|
2000-08-11 |
2014-07-18 |
Chugai Seiyaku Kabushiki Kaisha |
Preparaciones estabilizadas que contienen un anticuerpo
|
WO2002015908A1
(fr)
|
2000-08-18 |
2002-02-28 |
Takeda Chemical Industries, Ltd. |
Injections
|
MXPA03002262A
(es)
|
2000-09-18 |
2003-10-15 |
Idec Pharma Corp |
Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
|
KR100870123B1
(ko)
|
2000-10-20 |
2008-11-25 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 아고니스트 항체
|
AU2002210917B2
(en)
|
2000-10-20 |
2006-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
Degraded TPO agonist antibody
|
EP1327681A4
(en)
|
2000-10-20 |
2004-09-01 |
Chugai Pharmaceutical Co Ltd |
Degraded agonist antibodies
|
DE60133479T2
(de)
|
2000-10-20 |
2009-04-16 |
Chugai Seiyaku K.K. |
Modifizierter tpo-agonisten antikörper
|
WO2002078612A2
(en)
|
2001-04-02 |
2002-10-10 |
Euro-Celtique S.A. |
Thrombopoietin (tpo) synthebody for stimulation of platelet production
|
CN100475848C
(zh)
|
2001-05-18 |
2009-04-08 |
麒麟麦酒株式会社 |
抗trail-r抗体
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
DK1399484T3
(da)
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
BR0213303A
(pt)
|
2001-10-15 |
2005-06-07 |
Immunomedics Inc |
Proteìnas de ligação de alvejamento direto
|
EP1369431A4
(en)
|
2001-10-15 |
2005-01-12 |
Kirin Brewery |
ANTI-HLA-DR ANTIBODIES
|
EP1461001A4
(en)
|
2002-01-03 |
2010-03-31 |
Scripps Research Inst |
EPITOPE ASSOCIATED WITH CANCER
|
US20050118163A1
(en)
|
2002-02-14 |
2005-06-02 |
Hidefumi Mizushima |
Antibody-containing solution pharmaceuticals
|
WO2003072736A2
(en)
|
2002-02-21 |
2003-09-04 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
US20030232887A1
(en)
|
2002-04-10 |
2003-12-18 |
Johnson Douglas Giles |
Preparation and use of a stable formulation of allosteric effector compounds
|
AU2003227504A1
(en)
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
WO2003107218A1
(ja)
|
2002-05-31 |
2003-12-24 |
セレスター・レキシコ・サイエンシズ株式会社 |
相互作用予測装置
|
WO2003103723A2
(en)
|
2002-06-07 |
2003-12-18 |
Immunomedics, Inc. |
Neutrophil imaging methods in cyctic fibrosis
|
WO2003104425A2
(en)
|
2002-06-07 |
2003-12-18 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Novel stable anti-cd22 antibodies
|
CA2489004C
(en)
|
2002-06-13 |
2013-01-08 |
Crucell Holland B.V. |
Agonistic binding molecules to the human ox40 receptor
|
WO2003105782A2
(en)
|
2002-06-17 |
2003-12-24 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Specificity grafting of a murine antibody onto a human framework
|
US7115373B2
(en)
|
2002-06-27 |
2006-10-03 |
Genox Research, Inc. |
Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
|
DE60305919T2
(de)
|
2002-06-28 |
2007-01-18 |
Domantis Limited, Cambridge |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US20060058511A1
(en)
|
2002-08-27 |
2006-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing protein solution preparation
|
JP2004086682A
(ja)
|
2002-08-28 |
2004-03-18 |
Fujitsu Ltd |
機能ブロック設計方法および機能ブロック設計装置
|
CN1723036A
(zh)
|
2002-09-18 |
2006-01-18 |
奥索-麦克尼尔药品公司 |
增加血小板和造血干细胞产生的方法
|
NZ566812A
(en)
|
2002-09-18 |
2009-07-31 |
Ortho Mcneil Pharm Inc |
Methods of increasing platelet and hematopoietic stem cell production
|
US8158385B2
(en)
|
2002-10-11 |
2012-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death-inducing agent
|
EP1559433A4
(en)
|
2002-10-22 |
2009-11-04 |
Dainippon Sumitomo Pharma Co |
STABILIZED COMPOSITION
|
WO2004065611A1
(ja)
|
2003-01-21 |
2004-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の軽鎖スクリーニング方法
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
WO2004081048A1
(ja)
|
2003-03-13 |
2004-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
変異受容体に対するアゴニスト活性を有するリガンド
|
EP1609803A4
(en)
|
2003-03-31 |
2006-05-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
|
US8597911B2
(en)
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
AU2004287722A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-CD47 antibody
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
CA2548929A1
(en)
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death inducing agent
|
TW200530266A
(en)
*
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Method of reinforcing antibody activity
|
WO2005056605A1
(ja)
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
3量体以上の受容体を認識する改変抗体
|
US20070281327A1
(en)
|
2003-12-12 |
2007-12-06 |
Kiyotaka Nakano |
Methods of Screening for Modified Antibodies With Agonistic Activities
|
KR20070010046A
(ko)
|
2004-04-06 |
2007-01-19 |
제넨테크, 인크. |
Dr5 항체 및 그의 용도
|
WO2005100560A1
(ja)
|
2004-04-09 |
2005-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
細胞死誘導剤
|
AU2005249360B2
(en)
|
2004-04-12 |
2011-07-21 |
Medimmune, Llc |
Anti-IL-9 antibody formulations and uses thereof
|
TW200605906A
(en)
|
2004-05-11 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Remedy for thrombopenia
|
CA2585043A1
(en)
|
2004-10-22 |
2007-01-04 |
Medimmune, Inc. |
High affinity antibodies against hmgb1 and methods of use thereof
|
US20090062184A1
(en)
|
2005-03-24 |
2009-03-05 |
Dainippon Sumitomo Pharma Co., Ltd. |
Fine particulate preparation comprising complex of nucleic acid molecule and collagen
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc(Fv)2構造異性体
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
JPWO2006123724A1
(ja)
|
2005-05-18 |
2008-12-25 |
国立大学法人徳島大学 |
抗hla抗体を利用した新規医薬品
|
WO2006132341A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2部位特異的変異体
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
CA2610987C
(en)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
EP1925319B1
(en)
|
2005-06-10 |
2018-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(fv)2
|
EP1988927B1
(en)
|
2006-02-02 |
2016-04-13 |
The General Hospital Corporation |
Engineered antibody-stress protein fusions
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
BRPI0721097A2
(pt)
|
2006-12-11 |
2014-07-01 |
Hoffmann La Roche |
Formulação parenteral de anticorpo abeta
|
EP2175016A4
(en)
|
2007-06-25 |
2012-03-28 |
Forerunner Pharma Res Co Ltd |
ANTI-PROMININ-1 ANTIBODIES WITH ADCC ACTIVITY OR CDC ACTIVITY
|
CA2708869C
(en)
|
2007-12-21 |
2016-06-28 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|